Recent Cancer May Increase Risk for Guillain-Barr é Syndrome
FRIDAY, March 4, 2022 -- Recent cancer is associated with an increased risk for subsequent Guillain-Barré syndrome (GBS), according to a study published online March 2 in Neurology.
Lotte Sahin Levison, M.D., Ph.D., from Aarhus University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 4, 2022 Category: Pharmaceuticals Source Type: news
Study Shows Nerve Damage In Long Covid Even After Only Mild Covid-19
There have been reports of "long haulers" suffering Guillain-Barr é syndrome, mononeuritis multiplex, brachial plexitis, cranial neuropathies, orthostatic intolerance, and a variety of other neurological issues. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 3, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
Cancer may TRIPLE risk of developing nerve-numbing disorder Guillain-Barré syndrome
Researchers in Denmark, who studied 6million patients, found two per cent of those suffering from the potentially life-threatening condition recently received a cancer diagnosis. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2022 Category: Consumer Health News Source Type: news
Certain cancers may raise risk for Guillain-Barr é syndrome, study finds
People with lymphoma and blood cancers, as well as those who have lung, prostate or breast cancer, may be at higher risk for having new onset Guillain-Barr é syndrome, a study published by the journal Neurology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 2, 2022 Category: Consumer Health News Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Guillain-barre Syndrome After SARS-CoV-2 Infection Guillain-barre Syndrome After SARS-CoV-2 Infection
Is SARS-CoV-2 infection a trigger for Guillain-Barre syndrome? This findings of this study suggest that a strong relationship between the two is unlikely.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States
NEW BRUNSWICK, N.J., January 6, 2022 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of ...
Source: Johnson and Johnson - January 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
NEW BRUNSWICK, N.J., December 30, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization. The study, conducted by the South African Medical Research Council (SAMRC), showed that the Johnson & Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant variant...
Source: Johnson and Johnson - December 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Guillain-barre Syndrome Secondary to SARS-CoV2 Infection Guillain-barre Syndrome Secondary to SARS-CoV2 Infection
This case of a SARS-CoV2 patient with bilateral facial palsy underscores the need to be aware of any neurological manifestation generated by COVID-19, regardless of severity.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Guillain-Barre Syndrome Associated With COVID-19 Vaccination Guillain-Barre Syndrome Associated With COVID-19 Vaccination
How often does this condition occur after COVID-19 vaccination?Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 23, 2021 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news
Johnson & Johnson Statement on its COVID-19 Vaccine Following CDC ACIP Meeting
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson & Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson & Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi], ...
Source: Johnson and Johnson - December 16, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with today’s Positiv...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
NEW BRUNSWICK, N.J., December 9, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above. The WHO recommend the booster shot should be administered two to six months after the primary vaccination. SAGE advises WHO on global vaccine and immunization policies, and its recommendations provide guidance on the use of vaccines supplied through the COVAX Facility, a ...
Source: Johnson and Johnson - December 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match). T...
Source: Johnson and Johnson - December 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 vaccination and rare side effects including blood clotting, SPS (published 26th November 2021)
This resource provides information about rare side effects associated with COVID-19 vaccination focussing on blood clotting, myocarditis and Guillain-Barre syndrome. Incidence and vaccines implicated, and age specific advice as well as management strategies are included. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2021 Category: Consumer Health News Source Type: news
